Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis
Background: In the human central nervous system (CN), resting astrocytes do not visually show endothelin-1 (ET-1)-like immunoreactivity. In patients with multiple sclerosis (MS), an inflammatory disorder of the CNS, high levels of ET-1 are found in reactive astrocytes in demyelinated plaques. ET-1 m...
Autors principals: | Stéphanie Hostenbach, Miguel D’Haeseleer, Ron Kooijman, Jacques De Keyser |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
Frontiers Media S.A.
2020-01-01
|
Col·lecció: | Frontiers in Pharmacology |
Matèries: | |
Accés en línia: | https://www.frontiersin.org/article/10.3389/fphar.2019.01491/full |
Ítems similars
-
Definition, prevalence and predictive factors of benign multiple sclerosis
per: Tatjana Reynders, et al.
Publicat: (2017-06-01) -
Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan
per: Stéphanie Hostenbach, et al.
Publicat: (2019-03-01) -
Astrocytic β2-adrenergic receptors and multiple sclerosis
per: Jacques De Keyser, et al.
Publicat: (2004-03-01) -
Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
per: Joke Temmerman, et al.
Publicat: (2023-07-01) -
Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
per: Jeroen Van Schependom, et al.
Publicat: (2019-12-01)